Kapozid - combined tool, has hypotensive and diuretic effect. It is used to treat hypertension.

Pharmacological action

Active ingredients Kapozida reduce blood pressure, dilate the arteries, reduce platelet aggregation and increase renal and coronary blood flow.

Hydrochlorothiazide diuretic effect has moderate strength, while no effect on acid-base status. With prolonged use Kapozid improves blood flow to the ischemic myocardium.

Product form

Kapozid produced in the form of oval biconvex white tablets. Each tablet contains 50 mg of captopril and 25 mg hydrochlorothiazide.

Excipients - lactose, microcrystalline cellulose, stearic acid, magnesium stearate and corn starch. 14 tablets in a blister, 2 blisters in a carton box.

Indications Kapozida

According to the instructions Kapozid indicated for use in hypertension.


Kapozid of instruction is contraindicated in:

  • Hypertrophic obstructive cardiomyopathy;
  • Angioedema;
  • Bilateral renal artery stenosis or stenosis of the artery to a solitary kidney;
  • Hypotension;
  • Aortic stenosis and mitral stenosis;
  • Chronic heart failure;
  • Cardiogenic shock;
  • Tachycardia;
  • Condition after kidney transplantation;
  • Serious liver and kidney;
  • Hypersensitivity to the Kapozida, thiazide diuretics, and sulfonamide derivatives.
  • Primary hyperaldosteronism.

Not applicable Kapozid during pregnancy, lactation and under 18 years.

Instructions for use Kapozida

 Kapozid pills
 According to the instructions Kapozid taken one hour before a meal one tablet per day. The drug is used as symptomatic therapy.

At the beginning of treatment in the application of Kapozida sometimes there is an excessive drop in blood pressure, especially in heart or kidney failure.

side effects

According to the instructions Kapozid can cause various side effects:

  • Tachycardia, "tides" of blood to the skin of the face, dizziness, feeling of fever, headache, swelling of lower legs, palpitations, severe arterial hypotension with symptoms of dizziness; rarely - stroke, syncope, Raynaud's syndrome or myocardial infarction;
  • Thirst and dry mouth;
  • Dry cough, laryngitis, rhinitis, bronchospasm and sinusitis;
  • Hives and angioedema of face, extremities, lips, throat, mucous membranes, throat and tongue;
  • skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis. These effects may be accompanied by pain in muscles and joints, and a rise in temperature;
  • Abdominal pain, vomiting, loss of appetite, nausea, constipation or diarrhea, hemorrhagic pancreatitis, cholestatic jaundice, hepatitis, gingival hyperplasia, and alterations in taste;
  • Feeling tired; rarely - drowsiness, depression, depression, weakness, seizures, sleep disturbances, tinnitus, tremor, blurred vision;
  • Anemia, leukopenia, eosinophilia;
  • Impaired renal function and nephritis;
  • Hyperlipidemia, hyperuricemia, gipermagniemii, hyperglycemia;
  • Progression of myopia and impotence.

In overdose Kapozida may increase the severity of side effects.

Using the drug with other drugs should be considered:

  • The combined use of Kapozida with procainamide, as well as with other drugs that block tubular secretion, increases the risk of immunosuppressive action;
  • Kapozid reduces the effect of oral hypoglycemic drugs, epinephrine, norepinephrine and protivopodagricakih drugs;
  • When concomitant administration with diuretics, salicylates, adrenal hormones, laxatives, and amphotericin B may increase the side effects of the cardiovascular system;
  • Cimetidine increases the plasma concentration Kapozida.

storage conditions

Kapozid related to drug list B. Shelf life - 3 years.